Dow Up1.31% Nasdaq Up2.40%

More On GLPGF

Quotes

Charts

News & Info

Company

Analyst Coverage

  • Analyst Opinion
  • Analyst Estimates

Ownership

  • Major Holders
  • Insider Transactions
  • Insider Roster

Financials

  • Income Statement
  • Balance Sheet
  • Cash Flow

Galapagos NV (GLPGF)

-Other OTC
14.59 Oct 9, 1:55PM EDT
|Pre-Market : NaN
ProfileGet Profile for:
Galapagos NV
Industriepark Mechelen Noord
Generaal De Wittelaan L11 A3
Mechelen, 2800
Belgium - Map
Phone: 32 1 534 29 00
Fax: 32 1 534 29 01
Website: http://www.glpg.com

Details 
Index Membership:N/A
Sector:N/A
Industry:N/A
Full Time Employees:810

Business Summary 

Galapagos NV, a biotech company, discovers and develops small moleculesfor the treatment of cancer, immuno-inflammatory, osteoarthritis, rheumatoid arthritis, and cystic fibrosis diseases. The company’s products under development include GLPG0634, an orally-available, selective inhibitor of Janus kinase 1 that is in Phase IIB clinical trials for the treatment of rheumatoid arthritis (RA) and potentially other inflammatory diseases; and GLPG0778/555, an investigational compound, which is in Phase II studies for the treatment of lupus, ulcerative colitis, and psoriasis. It is also developing GSK2586184, which is in Phase II clinical trials for the treatment of immuno-inflammatory diseases; GLPG0974, an orally available small molecule that is in Phase IB clinical trials to treat neutrophil-driven inflammatory conditions, such as inflammatory bowel disease; and GLPG1205, a drug candidate that completed Phase I clinical trial for the treatment of inflammatory bowel disease. The company has strategic alliances with GlaxoSmithKline, Janssen Pharmaceutica NV, Servier, and AbbVie. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Galapagos NV

Key Executives 
 PayExercised
Mr. Onno van de Stolpe ,
Co-Founder, Chief Exec. Officer, Managing Director, Exec. Director and Chairman of Exec. Committee
1.06MN/A
Ms. Laure Verhaegen ,
Interim Chief Financial Officer and VP of Fin.
N/AN/A
Dr. Piet Wigerinck ,
Chief Scientific Officer and Member of Exec. Committee
N/AN/A
Ms. Elizabeth Goodwin ,
Head of Corp. Communications & Investor Relations
N/AN/A
Dr. Andre Hoekema Ph.D.,
Sr. VP of Corp. Devel. and Member of Exec. Committee
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.